Katie Price warns 'Harvey's going to look different' as she issues worrying health update

Katie Price has disclosed that "a lot's gonna change" for her son, Harvey, who will "look different" when he starts a new medication. In a recent episode of The Katie Price Show, the former glamour model, who was broadcasting from Dubai, revealed that her son, Harvey Price, is set to switch from college to independent living.

Katie decided to place Harvey, who has ADHD, autism, Prader-Willi Syndrome, and septo-optic dysplasia, into full-time care in a residential college in 2021 so he could learn new skills and become more independent.

In July 2024, she revealed that she was forced to take Harvey out of his £350,000-per-year college, as the local authority wouldn't pay for him because he was deemed to have "no healthcare issues".

READ MORE: David Beckham sends public message to 'missing' Brooklyn amid family's fierce feud

READ MORE: Diogo Jota's heartbreaking promise to three kids before dying in tragic car crash

Katie has now revealed that Harveyis due to start taking the weight-loss drug Mounjaro and will attend a place in Southampton that helps people living with Prader-Willi Syndrome.

She said: "And they've had a few people there, within months, just losing weight because they know how to deal with it.

"You know, in a couple of years, Harvey's gonna look different with that place... the Mounjaro, like? And then he gets the proper little life back, because at the moment, where he's so big, he's just out of breath. So, a lot's gonna change for Harv when he moves.

"I don't... I can't wait to see what he's gonna look like. Because everyone's so used to Harvey being so big — imagine him being a lot smaller. It'll be so weird."

Mounjaro, the brand name for tirzepatide, is an antidiabetic medication that was approved by the National Institute for Health and Care Excellence (NICE) in 2024 for the treatment of obesity on the NHS.

As of last month, GPs across England could prescribe the drug to severely obese people for this purpose, initially to those with a BMI score of more than 40 during the first year.

Patients who can access the medication will also have other long-term health conditions, including high blood pressure (otherwise known as hypertension), type 2 diabetes, dyslipidaemia, or sleep apnoea.

It's believed that about 1.5 million people take weight loss drugs across Britain, although much of this is via private prescriptions or through dedicated weight loss services.

According to the NHS, as with all medications, tirzepatide can have side effects, including nausea, indigestion, constipation, and diarrhoea. More serious side effects could include pancreatitis, low blood sugar, and gallstones.

Speaking about the rollout, Dr Claire Fuller, from NHS England, said: "This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today.

"We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health, and greater access to weight loss drugs will make a significant difference to the lives of those people."